• 1
    Bennett H, Einarson A, Taddio A, Koren G, Einarson T. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004; 103: 698709.
  • 2
    Bennett H, Einarson A, Taddio A, Koren G, Einarson T. Depression during pregnancy: overview of clinical factors. Clin Drug Investig 2004; 24: 15779.
  • 3
    Nakhai-Pour H, Broy P, Bérard A. Use of antidepressants during pregnancy and the risk of spontaneous abortion. Can Med Assoc J 2010; 182: 10317.
  • 4
    Ramos E, St-Andre M, Berard A. Association between antidepressant use during pregnancy and infants born small for gestational age. Can J Psychiatry 2010; 55: 64352.
  • 5
    Ramos E, St-Andre M, Rey E, Oraichi D, Berard A. Duration of antidepressant use during pregnancy and risk of major congenital malformations. Br J Psychiatry 2008; 192: 34450.
  • 6
    Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007; 80: 1827.
  • 7
    Bolte A, van Geijn H, Dekker G. Pathophysiology of preeclampsia and the role of serotonin. Eur J Obstet Gynecol 2001; 95: 1221.
  • 8
    Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998; 59: 5028.
  • 9
    Toh S, Mitchell A, Louik C, Werler M, Chambers C, Hernández-Diaz S. Selective serotonin reuptake inhibitor use and risk of gestational hypertension. Am J Psychiatry 2009; 166: 3208.
  • 10
    Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010; 40: 172333.
  • 11
    Berard A, Lacasse A. Validity of perinatal pharmacoepidemiologic studies using data from the RAMQ administrative database. Can J Clin Pharmacol 2009; 16: e3609.
  • 12
    World Health Organization. International Classification of Diseases, Ninth Revision. Geneva: World Health Organization, 1997.
  • 13
    Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995; 48: 9991009.
  • 14
    Levy AR, Mayo NE, Grimard G. Rates of transcervical and pertrochanteric hip fractures in the province of Quebec, Canada, 1981–1992. Am J Epidemiol 1995; 142: 42836.
  • 15
    Roy E, Haley N, Leclerc P, Sochanski B, Boudreau J-F, Boivin J-F. Mortality in a cohort of street youth in Montreal. J Am Med Assoc 2004; 292: 56974.
  • 16
    Magee L, Helewa M, Moutquin J, von Dadelszen P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can 2008; 30: S915.
  • 17
    Essebag V, Genest J Jr, Suissa S, Pilote L. The nested case-control study in cardiology. Am Heart J 2003; 146: 58190.
  • 18
    Bryson C, Ioannou G, Rulyak S, Critchlow C. Association between gestational diabetes and pregnancy-induced hypertension. Am J Epidemiol 2003; 158: 114853.
  • 19
    Ros H, Cnattingius S, Lipworth L. Comparison of risk factors for preeclampsia and gestational hypertension in a population-based cohort study. Am J Epidemiol 1998; 147: 106270.
  • 20
    Ramos E, Oraichi D, Rey E, Blais L, Berard A. Prevalence and predictors of antidepressant use in a cohort of pregnant women. BJOG 2007; 114: 105564.
  • 21
    Toh S, Mitchell AA, Werler MM, Hernandez-Diaz S. Sensitivity and specificity of computerized algorithms to classify gestational periods in the absence of information on date of conception. Am J Epidemiol 2008; 167: 63340.
  • 22
    Van Nueten J. Serotonin and the blood vessel wall. J Cardiovasc Pharmacol 1985; 7: (Suppl. 7): S4951.
  • 23
    Ortiz J, Artigas F. Effects of monoamine uptake inhibitors on extracellular and platelet 5-hydroxytryptamine in rat blood: different effects of clomipramine and fluoxetine. Br J Pharmacol 1992; 105: 9416.
  • 24
    Skop BP, Brown TM. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 1996; 37: 126.
  • 25
    Finkel MS, Laghrissi-Thode F, Pollock BG, Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull 1996; 32: 6538.
  • 26
    Yaron I, Shirazi I, Judovich R, Levartovsky D, Caspi D, Yaron M. Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures. Arthritis Rheum 1999; 42: 25618.
  • 27
    Kurki T, Hiilesmaa V, Raitasalo R, Mattila H, Ylikorkala O. Depression and anxiety in early pregnancy and risk for preeclampsia. Obstet Gynecol 2000; 95: 48790.
  • 28
    Qiu C, Sanchez S, Lam N, Garcia P, Williams M. Associations of depression and depressive symptoms with preeclampsia: results from a Peruvian case-control study. BMC Womens Health 2007; 7: 17.
  • 29
    Berard A, Nakhai-Pour H, Kulaga S. Impact of missing data on potential confounders in perinatal pharmacoepidemiologic studies using administrative databases. Can J Clin Pharmacol 2009; 16: e20233.
  • 30
    Suissa S, Garbe E. Primer: administrative health databases in observational studies of drug effects – advantages and disadvantages. Nat Clin Pract Rheumatol 2007; 3: 72532.
  • 31
    De Jong van den Berg LT, Feenstra N, Sorensen HT, Cornel MC. Improvement of drug exposure data in a registration of congenital anomalies. Pilot-study: pharmacist and mother as sources for drug exposure data during pregnancy. EuroMAP Group. Europen Medicine and Pregnancy Group. Teratology 1999; 60: 336.